Summit Therapeutics is on the Cruelty Free Investing list for exploiting animals because the company does animal testing to research, develop and commercialize some of their medical products and therapies.
The company stated in the following article that they conduct pre-clinical trials of their drugs on animals.
“We’re now in a Phase 2 trial, called the PhaseOut DMD, where we have the opportunity, for the first time, to see if utrophin modulation can demonstrate the disease modifying results in patients that we have already seen in animal models of DMD.” Read the full article
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. [Source: Reuters]
Company Website: http://www.summitplc.com